N,N-(4-methyl-3-nitrophenyl)[4-(pyridin-3-yl)-pyrimidin-2-yl]amine | 796738-67-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N,N-(4-methyl-3-nitrophenyl)[4-(pyridin-3-yl)-pyrimidin-2-yl]amine
• 英文别名: N-(4-Methyl-5-nitrophenyl)-4-(3-pyridinyl)-2-pyrimidinamine；N-(4-methyl-3-nitrophenyl)-4-(3-pyridyl)-2-pyrimidine-amine；N-(4-methyl-3-nitrophenyl)-4-(pyridin-3-yl)-2-pyrimidine-amine；N-(4-methyl-3-nitrophenyl)-4-pyridin-3-ylpyrimidin-2-amine
• CAS: 796738-67-5
• 化学式: C₁₆H₁₃N₅O₂
• 分子量: 307.312
• InChiKey: YQYKGPRQACRBHY-UHFFFAOYSA-N

物化性质

• 沸点：
  535.5±60.0 °C(Predicted)
• 密度：
  1.344±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  96.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N,N-(4-methyl-3-nitrophenyl)[4-(pyridin-3-yl)-pyrimidin-2-yl]amine 在 palladium 10% on activated carbon 、 氢气 作用下， 以 四氢呋喃 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 生成 N-(3-氨基-4-甲基苯基)-4-(吡啶-3-基)-2-嘧啶-胺
  参考文献：
  名称：

  在 Bcr-Abl 和 FMS、KIT 和 PDGF 受体之间具有改变的特异性的新型伊马替尼衍生物

  摘要：

  伊马替尼是临床上重要的 ATP 类似物抑制剂，靶向细胞内 Abl 激酶和 PDGF 受体家族的酪氨酸激酶结构域。伊马替尼彻底改变了慢性粒细胞白血病的治疗，慢性粒细胞白血病是由致癌基因 Bcr-Abl 和某些含有 PDGF 受体家族致癌突变的实体瘤引起的。作为领先的激酶抑制剂，伊马替尼还提供了一个很好的模型系统来研究药物设计的变化如何影响生物活性，这是合理药物设计的重要考虑因素。在此我们报告了一系列新的伊马替尼衍生物，由于苯基和N的修饰，它们通常对 PDGF 受体家族具有更大的活性，而对 Abl 的活性较差-甲基哌嗪环。这些新化合物为针对治疗上重要的 PDGF 受体家族的进一步药物开发提供了一个平台，它们还提供了对具有改变生物活性的药物工程的深入了解。

  DOI：

  10.1002/cmdc.200900394
• 作为产物：
  描述：

  3-乙酰基吡啶 在 sodium hydroxide 作用下， 以 水 、 正丁醇 为溶剂， 反应 18.0h， 生成 N,N-(4-methyl-3-nitrophenyl)[4-(pyridin-3-yl)-pyrimidin-2-yl]amine
  参考文献：
  名称：

  Facile Synthesis of 2-Phenylquinoline-4-carboxamide Derivatives with Variant Structural Features

  摘要：

  The quinoline scaffold is an important class of heterocyclic compounds that possesses diverse chemotherapeutic activities. Thus, the 2-phenylquinoline-4-carboxamide derivatives containing a variety of moieties, such as 2-(2-furanyl)-1,3,4-oxadiazole, N-(2-methylphenyl)-4-(3-pyridinyl)-2-pyrimidinamine, 4,4'-bithiazole, purine, adamantine and resorcinol, have been designed and synthesized via Suzuki coupling, acid-base coupling and other typical reactions.

  DOI：

  10.3987/com-14-12939

文献信息

• Functionally substituted Schiff bases in reduction reactions
  作者：E. V. Koroleva、K. N. Gusak、Zh. V. Ignatovich、A. L. Ermolinskaya

  DOI：10.1134/s1070428013020073

  日期：2013.2

  Functionally substituted Schiff bases obtained by the condensation of nitroaniline, pyrimidinylaminoaniline, 5-aminoquinoline, 5-aminoquinaldine derivatives with 4-methylformylbenzoate were studied in the reactions of sodium borohydride with acidic activators, hydrazine hydrate in the presence of Raney nickel, Raney alloy in the presence of potassium hydroxide. By the reduction of azomethines new benzyl

  在硼氢化钠与酸性活化剂，水合肼在阮内镍，阮内合金存在下的反应中，研究了硝基苯胺，嘧啶基氨基苯胺，5-氨基喹啉，5-氨基喹喔啉衍生物与4-甲基甲酰基苯甲酸酯缩合得到的功能取代的席夫碱。氢氧化钾的存在。通过偶氮甲胺的还原，获得了苯胺，喹啉胺，芳基氨基嘧啶和苯二胺的新苄基衍生物。
• [EN] N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF<br/>[FR] DERIVES DE N-PHENYL-2-PYRIMIDINE-AMINE ET PROCEDE DE PREPARATION DE CEUX-CI
  申请人：IL YANG PHARM CO LTD

  公开号：WO2004099186A1

  公开（公告）日：2004-11-18

  The present invention relates to an N-phenyl-2-pyrimidine-amine derivative showing a superior effect on tumor, lung cancer, gastric cancer, etc. of warm-blooded animals and its salt. The present invention also relates to a process for preparing the compound and a pharmaceutical composition for the prevention and treatment of such diseases as tumor, lung cancer, gastric cancer, etc., which comprises the compound as an active ingredient.

  本发明涉及一种对温血动物的肿瘤、肺癌、胃癌等具有优越效果的N-苯基-2-嘧啶胺衍生物及其盐。本发明还涉及一种制备该化合物的方法和一种药物组合物，用于预防和治疗肿瘤、肺癌、胃癌等疾病，其包括该化合物作为活性成分。
• [EN] N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF<br/>[FR] DERIVES DE N-PHENYL-2-PYRIMIDINE-AMINE ET PROCEDE D'ELABORATION CORRESPONDANT
  申请人：IL YANG PHARM CO LTD

  公开号：WO2004099187A1

  公开（公告）日：2004-11-18

  The present invention relates to an N-Phenyl-2-pyrimidine-aminine derivative showing a superior effect on lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or accute leukemia, hematologic malignancy, encephalophyma, bladder cancer, rectal cancer or cervical cancer, etc. of warm blooded animals and its salt. The present invention also relates to a process for preparing the compound, and to a pharmaceutical composition for the treatment of the above various disease, which comprises an effective amount of the compound as an active ingredient together with pharmaceutically acceptable inert carriers.

  本发明涉及一种对暖血动物的肺癌、胃癌、结肠癌、胰腺癌、肝癌、前列腺癌、乳腺癌、慢性或急性白血病、血液恶性肿瘤、脑瘤、膀胱癌、直肠癌或宫颈癌等表现出优越效果的N-苯基-2-嘧啶-胺衍生物及其盐。本发明还涉及一种制备该化合物的方法，以及一种用于治疗上述各种疾病的药物组合物，其包括作为活性成分的该化合物的有效量，以及药学上可接受的惰性载体。
• N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
  申请人：IL YANG PHARM. CO., LTD.

  公开号：US20040248918A1

  公开（公告）日：2004-12-09

  The present invention relates to an N-phenyl-2-pyrimidine-amine derivative showing a superior effect on lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or acute leukemia, hematologic malignancy, encephalophyma, bladder cancer, rectal cancer, or cervical cancer, etc. of warm-blooded animals and its salt. The present invention also relates to a process for preparing the compound, and to a pharmaceutical composition for the treatment of the above various diseases, which comprises an effective amount of the compound as an active ingredient together with pharmaceutically acceptable inert carriers.

  本发明涉及一种对温血动物的肺癌、胃癌、结肠癌、胰腺癌、肝癌、前列腺癌、乳腺癌、慢性或急性白血病、血液恶性肿瘤、脑膨出、膀胱癌、直肠癌或宫颈癌等表现出优越效果的N-苯基-2-嘧啶胺衍生物及其盐。本发明还涉及一种制备该化合物的方法，以及一种用于治疗上述各种疾病的药物组合物，其中包括作为活性成分的该化合物的有效量，以及药用可接受的惰性载体。
• Catalytic Activity of Nickel Nanoparticles in the Reaction of Reduction of Nitroarenes
  作者：Zh. V. Ignatovich、A. L. Ermolinskaya、Ya. M. Katok、E. V. Koroleva、A. N. Eremin、V. E. Agabekov

  DOI：10.1134/s1070363218030064

  日期：2018.3

  Techniques for the production of nickel and nickel-cobalt nanoparticles and of their composites with polyvinylpyrrolidone were developed. The catalytic activity of the resulting compounds towards reduction of substituted nitroarenes was examined.